BioArctic AB (publ) (STO:BIOA.B)
237.00
+3.60 (1.54%)
Aug 14, 2025, 5:21 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 1.29B SEK in the quarter ending March 31, 2025, with 4,251.06% growth. This brings the company's revenue in the last twelve months to 1.52B, up 501.62% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.52B
Revenue Growth
+501.62%
P/S Ratio
13.62
Revenue / Employee
13.08M
Employees
107
Market Cap
20.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.31B |
Getinge AB | 35.50B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
Camurus AB | 2.27B |
Bonesupport Holding AB | 1.06B |
AddLife AB | 10.44B |
BioArctic AB News
- 14 days ago - Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 - PRNewsWire
- 14 days ago - BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile - PRNewsWire
- 23 days ago - Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 - PRNewsWire
- 4 weeks ago - The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association - PRNewsWire
- 7 weeks ago - BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize - PRNewsWire
- 2 months ago - BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - PRNewsWire
- 2 months ago - BioArctic's Capital Markets Day 2025 - entering a new era of growth - PRNewsWire
- 3 months ago - Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) - PRNewsWire